Autologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells therapy (Shanghai Cell Therapy Research Institute)

N/A

Report date: 2024/11/18 20:00:28

Base Information

Drug NameAutologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells therapy (Shanghai Cell Therapy Research Institute)
Drug Alias NamePD-1 antibody expressing mesoCAR-T cells therapy (Shanghai Cell Therapy Research Institute)
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMesothelin modulatorsProgrammed cell death protein 1 blockers
TargetsMesothelinProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Cell Therapy Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Cell Therapy Research Institute
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A